azimilide has been researched along with Arrhythmia in 36 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 10 (27.78) | 18.2507 |
2000's | 24 (66.67) | 29.6817 |
2010's | 2 (5.56) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Jia, L; Sun, H | 1 |
Al-Khalidi, HR; Brum, JM; Dorian, P; Dunnmon, PM; Hohnloser, SH; Holroyde, MJ; Kowey, P; Pratt, CM | 1 |
Cannom, DS; Gidney, B | 1 |
Ducroq, J; Legrand, JC; Puddu, PE; Rouet, R; Sallé, L | 1 |
Tang, YQ; Wang, XJ; Yang, Q; You, QD | 1 |
Grönefeld, GC; Hohnloser, SH | 1 |
Pratt, CM | 1 |
Li, WZ | 1 |
Al-Khalidi, HR; Brum, JM; Camm, AJ; Holroyde, MJ; Karam, R; Pratt, CM; Schwartz, PJ; Sonnenblick, EH; Spyt, MJ | 1 |
Dong, DL; Du, ZM; Li, Z; Song, WH; Wang, HZ; Yang, BF | 1 |
Brendorp, B; Elming, H; Køber, L; Pedersen, OD; Pehrson, S; Torp-Petersen, C | 1 |
Carlson, M | 1 |
Ducouret, P; Ducroq, J; Gérard, JL; Puddu, PE; Rouet, R; Sallé, L; Tabourel, C | 1 |
Connolly, S; Kerr, C; Kowey, P; Page, RL; Pritchett, EL; Wilkinson, WE | 1 |
Carlsson, L; Jacobson, I; Löfberg, L | 1 |
Al-Khalidi, HR; Borggrefe, M; Brum, JM; Camm, AJ; Dorian, P; Holroyde, MJ; Marcello, SR; Pratt, CM; Schwartz, PJ | 1 |
Guo, D; Kowey, PR; Liu, T; Wu, Y; Yan, GX; Zhao, X | 1 |
Grant, AO; Tranquillo, J | 1 |
Connolly, S; Page, RL; Pritchett, EL; Wilkinson, WE | 1 |
Sharma, S | 1 |
Brooks, RR; Carpenter, JF; Maynard, AE; Miller, KE | 1 |
Brooks, RR; Drexler, AP; Micklas, JM | 1 |
Benn, DR; Kostreva, DR; Lowe, ER; Maynard, AE; Mittelstadt, SW | 1 |
Camm, AJ; Karam, R; Pratt, CM | 1 |
Brooks, RR; Corey, AE; Karam, R; Marcello, S; Moore, A | 1 |
Sager, PT | 2 |
Chino, D; Hashimoto, K; Xue, Y; Yamada, C | 1 |
Dorian, P; Newman, D; Qi, XQ | 1 |
Al-Khalidi, H; Brooks, RR; Drexler, AP; Kostreva, DR; Maynard, AE | 1 |
Clemett, D; Markham, A | 1 |
Abrol, R; Page, RL | 1 |
Camm, AJ | 1 |
Reiffel, JA | 1 |
10 review(s) available for azimilide and Arrhythmia
Article | Year |
---|---|
[The research practice of anti-arrhythmic agents targeting on potassium ion channel].
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dronedarone; Humans; Hydantoins; Imidazolidines; Molecular Structure; Piperazines; Potassium Channel Blockers; Potassium Channels | 2011 |
[Drug therapy of ventricular arrhythmias - a contemporary perspective].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium Channel Blockers; Clinical Trials as Topic; Coronary Disease; Death, Sudden, Cardiac; Defibrillators, Implantable; Double-Blind Method; Follow-Up Studies; Heart Failure; Heart Ventricles; Humans; Hydantoins; Imidazoles; Imidazolidines; Meta-Analysis as Topic; Piperazines; Placebos; Primary Prevention; Prospective Studies; Quality of Life; Randomized Controlled Trials as Topic; Risk Factors; Time Factors | 2002 |
Pure class III agents for prevention of sudden cardiac death.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Comorbidity; Death, Sudden, Cardiac; Europe; Humans; Hydantoins; Imidazoles; Imidazolidines; Middle Aged; Myocardial Infarction; Phenethylamines; Piperazines; Randomized Controlled Trials as Topic; Sotalol; Sulfonamides; Survival Analysis; Treatment Outcome | 2003 |
A benefit-risk assessment of class III antiarrhythmic agents.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Combined Modality Therapy; Defibrillators, Implantable; Dronedarone; Heart Conduction System; Humans; Hydantoins; Imidazolidines; Ion Transport; Life Tables; Membrane Potentials; Meta-Analysis as Topic; Phenethylamines; Piperazines; Risk Assessment; Sotalol; Sulfonamides; Survival Analysis; Torsades de Pointes; Treatment Outcome | 2004 |
Antiarrhythmic drugs: present and future.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Design; Humans; Hydantoins; Imidazolidines; Ion Channels; Piperazines; Sotalol | 2007 |
Azimilide dihydrochloride, a novel antiarrhythmic agent.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dogs; Humans; Hydantoins; Imidazoles; Imidazolidines; Piperazines; Potassium Channel Blockers | 1998 |
New advances in class III antiarrhythmic drug therapy.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Denmark; Humans; Hydantoins; Imidazoles; Imidazolidines; Phenethylamines; Piperazines; Postoperative Complications; Potassium Channel Blockers; Randomized Controlled Trials as Topic; Sulfonamides | 1999 |
New advances in class III antiarrhythmic drug therapy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrophysiology; Humans; Hydantoins; Imidazoles; Imidazolidines; Phenethylamines; Piperazines; Sotalol; Sulfonamides | 2000 |
Azimilide dihydrochloride: a new class III anti-arrhythmic agent.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Humans; Hydantoins; Imidazoles; Imidazolidines; Piperazines | 2000 |
Clinical differences between the newer antiarrhythmic agents.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bridged Bicyclo Compounds, Heterocyclic; Cyclopropanes; Dronedarone; Heart Conduction System; Humans; Hydantoins; Imidazoles; Imidazolidines; Phenethylamines; Piperazines; Sulfonamides | 2000 |
5 trial(s) available for azimilide and Arrhythmia
Article | Year |
---|---|
Azimilide reduces emergency department visits and hospitalizations in patients with an implantable cardioverter-defibrillator in a placebo-controlled clinical trial.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Defibrillators, Implantable; Emergency Service, Hospital; Hospitalization; Humans; Hydantoins; Imidazolidines; Middle Aged; Piperazines | 2008 |
Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Double-Blind Method; Female; Heart Rate; Humans; Hydantoins; Imidazoles; Imidazolidines; Life Tables; Male; Middle Aged; Myocardial Infarction; Neutropenia; Piperazines; Potassium Channel Blockers; Risk Factors; Survival Analysis; Torsades de Pointes; Treatment Outcome; Ventricular Dysfunction, Left | 2004 |
Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Female; Heart Rate; Humans; Hydantoins; Imidazolidines; Long QT Syndrome; Male; Middle Aged; Piperazines; Syncope; Torsades de Pointes; Treatment Outcome | 2006 |
Azimilide for the treatment of atrial fibrillation, atrial flutter, and paroxysmal supraventricular tachycardia: results of a randomized trial and insights on the concordance of symptoms and recurrent arrhythmias.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Endpoint Determination; Female; Humans; Hydantoins; Imidazolidines; Male; Piperazines; Secondary Prevention; Tachycardia, Supraventricular; Treatment Outcome | 2008 |
The azimilide post-infarct survival evaluation (ALIVE) trial.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Double-Blind Method; Drug Administration Schedule; Female; Heart Rate; Humans; Hydantoins; Imidazoles; Imidazolidines; Male; Middle Aged; Myocardial Infarction; Piperazines; Risk Factors; Stroke Volume; Survival Rate | 1998 |
21 other study(ies) available for azimilide and Arrhythmia
Article | Year |
---|---|
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Azimilide: another effort to prevent implantable cardioverter-defibrillator shocks and their sequelae why it is important and how it works.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Defibrillators, Implantable; Humans; Hydantoins; Imidazolidines; Piperazines | 2008 |
I(Kr) vs. I(Ks) blockade and arrhythmogenicity in normoxic rabbit Purkinje fibers: does it really make a difference?
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chromans; Delayed Rectifier Potassium Channels; Epinephrine; Hydantoins; Imidazolidines; In Vitro Techniques; Male; Phenethylamines; Piperazines; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Purkinje Fibers; Rabbits; Sotalol; Sulfonamides | 2011 |
[Progress in the clinical use of anti-arrhythmic drugs (I)].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Child; Clinical Trials as Topic; Humans; Hydantoins; Imidazoles; Imidazolidines; Phenethylamines; Piperazines; Sulfonamides | 2003 |
Acidification alters antiarrhythmic drug blockade of the ether-a-go-go-related Gene (HERG) Channels.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Delayed Rectifier Potassium Channels; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Hydantoins; Hydrogen-Ion Concentration; Imidazoles; Imidazolidines; Myocardial Ischemia; Oocytes; Patch-Clamp Techniques; Phenethylamines; Piperazines; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quinidine; Sulfonamides; Transfection; Xenopus | 2004 |
Azimilide dihydrochloride.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Hydantoins; Imidazolidines; Piperazines | 2005 |
Electrophysiological effects of azimilide in an in vitro model of simulated-ischemia and reperfusion in guinea-pig ventricular myocardium.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chromans; Dose-Response Relationship, Drug; Female; Guinea Pigs; Heart Ventricles; Hydantoins; Imidazolidines; In Vitro Techniques; Male; Myocardial Ischemia; Myocardial Reperfusion Injury; Phenethylamines; Piperazines; Potassium Channel Blockers; Sulfonamides; Time Factors | 2005 |
Electrophysiological and antiarrhythmic effects of the novel antiarrhythmic agent AZD7009: a comparison with azimilide and AVE0118 in the acutely dilated right atrium of the rabbit in vitro.
Topics: Analysis of Variance; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Biphenyl Compounds; Dilatation, Pathologic; Heart Atria; Hydantoins; Imidazolidines; In Vitro Techniques; Organic Chemicals; Piperazines; Rabbits | 2006 |
Cumulative experience of azimilide-associated torsades de pointes ventricular tachycardia in the 19 clinical studies comprising the azimilide database.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Databases, Factual; Dose-Response Relationship, Drug; Electrocardiography; Female; Humans; Hydantoins; Imidazolidines; Male; Middle Aged; Piperazines; Time Factors; Torsades de Pointes | 2006 |
L-type calcium current reactivation contributes to arrhythmogenesis associated with action potential triangulation.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium Channel Blockers; Calcium Channels, L-Type; Guinea Pigs; Hydantoins; Imidazolidines; In Vitro Techniques; Myocytes, Cardiac; Nicardipine; Patch-Clamp Techniques; Phenethylamines; Piperazines; Rabbits; Sulfonamides | 2007 |
Action potential and QT prolongation not sufficient to cause Torsade de Pointes: role of action potential triangulation.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium Channel Blockers; Calcium Channels, L-Type; Guinea Pigs; Hydantoins; Imidazolidines; Myocytes, Cardiac; Nicardipine; Patch-Clamp Techniques; Phenethylamines; Piperazines; Rabbits; Sulfonamides; Torsades de Pointes | 2007 |
Efficacy of the class III antiarrhythmic agent azimilide in rodent models of ventricular arrhythmia.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Chloroform; Constriction; Coronary Vessels; Disease Models, Animal; Dose-Response Relationship, Drug; Guinea Pigs; Heart Rate; Hydantoins; Imidazoles; Imidazolidines; Male; Mice; Ouabain; Piperazines; Propranolol; Rats; Rats, Sprague-Dawley | 1996 |
Suppression of inducible ventricular arrhythmias by intravenous azimilide in dogs with previous myocardial infarction.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium Channel Blockers; Dogs; Electrocardiography; Heart; Hemodynamics; Hydantoins; Imidazoles; Imidazolidines; Infusions, Intravenous; Male; Myocardial Infarction; Piperazines; Sotalol | 1996 |
Effects of azimilide and d,l-sotalol on the heart rate and blood pressure response to isoproterenol in anesthetized rats.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Electrocardiography; Heart Rate; Hydantoins; Imidazoles; Imidazolidines; Isoproterenol; Male; Piperazines; Rats; Rats, Sprague-Dawley; Sotalol | 1997 |
Effects of azimilide, a KV(r) and KV(s) blocker, on canine ventricular arrhythmia models.
Topics: Anesthetics; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dogs; Epinephrine; Female; Halothane; Hydantoins; Imidazoles; Imidazolidines; Infusions, Intravenous; Injections, Intravenous; Male; Myocardial Reperfusion Injury; Pentobarbital; Piperazines; Potassium Channel Blockers; Ventricular Fibrillation | 1999 |
Azimilide. NE 10064, Stedicor.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dogs; Drug Interactions; Drugs, Investigational; Guinea Pigs; Humans; Hydantoins; Imidazoles; Imidazolidines; In Vitro Techniques; Piperazines; Potassium Channel Blockers | 1999 |
[Azimilide: Search for an effective and well-tolerated anti-arrhythmia agent].
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death; Death, Sudden; Humans; Hydantoins; Imidazoles; Imidazolidines; Piperazines | 1999 |
The class III effect of azimilide is not associated with reverse use-dependence in open-chest dogs.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Cardiac Pacing, Artificial; Delayed Rectifier Potassium Channels; Dogs; Dose-Response Relationship, Drug; Female; Heart Rate; Hydantoins; Imidazoles; Imidazolidines; Male; Piperazines; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Refractory Period, Electrophysiological; Ventricular Fibrillation | 1999 |
Proarrhythmia of azimilide and other class III antiarrhythmic agents in the adrenergically stimulated rabbit.
Topics: Adrenergic alpha-Agonists; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, Animal; Female; Hemodynamics; Hydantoins; Imidazoles; Imidazolidines; Male; Methoxamine; Phenethylamines; Piperazines; Procainamide; Quaternary Ammonium Compounds; Rabbits; Sotalol; Sulfonamides | 2000 |
Azimilide.
Topics: Administration, Oral; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, Animal; Dogs; Headache; Humans; Hydantoins; Imidazoles; Imidazolidines; Piperazines; Recurrence; Torsades de Pointes | 2000 |
Is it rational, reasonable or excessive, and consistently applied? One view of the increasing FDA emphasis on safety first for the release and use of antiarrhythmic drugs for supraventricular arrhythmias.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Approval; Drugs, Generic; Heart Ventricles; Humans; Hydantoins; Imidazoles; Imidazolidines; Phenethylamines; Piperazines; Sotalol; Sulfonamides; United States; United States Food and Drug Administration | 2001 |